Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 28, 2015 11:00 PM ET

Biotechnology

Company Overview of Octapharma AG

Company Overview

Octapharma AG develops, produces, and sells human proteins that are derived from human plasma and human cell-lines. The company provides haematology products, including Nuwiq, a human coagulation factor VIII used for the treatment and prophylaxis of bleeding in all age groups with haemophilia A; Octanate, a human factor VIII/von Willebrand factor (VWF) concentrate, which is used for the treatment and prophylaxis of bleeding in patients with haemophilia A; wilate, a human VWF concentrate that is used for the treatment of patients with von Willebrand disease and haemophilia A; and octanine, a human factor IX concentrate that is used for the prophylaxis and treatment of bleeding in haemophilia ...

Seidenstrasse 2

Lachen,  8853

Switzerland

Founded in 1983

5,683 Employees

Phone:

41 55 451 21 21

Fax:

41 55 451 21 10

Key Executives for Octapharma AG

Chairman of Management Board
Chief Financial Officer and Member of Management Board
Member of Management Board and President of Octapharma Plasma Inc Usa
Member of Management Board and President for Octapharma Usa Inc
Senior Vice President of R&D Plasma - Vienna
Compensation as of Fiscal Year 2015.

Octapharma AG Key Developments

Octapharma AG Reports Earnings Results for the Year Ended December 31, 2014

Octapharma AG reported that net profit for the year ended December 31, 2014 was EUR 236.14 million, compared to EUR 124.40 million for the year ended December 31, 2013. Revenue for the year ended December 31, 2014 was EUR 1.28 billion, compared to EUR 1.15 billion for the year ended December 31, 2013. Operating income for the year ended December 31, 2014 was EUR 271.19 million, compared to EUR 149.92 million for the year ended December 31, 2013.

Octapharma Consider Building Pharmaceutical Plant in Russia

Octapharma announced it is considering building a plant in Russia to produce blood plasma medicine for patients with hemophilia. The company is considering carrying out its own investment project in the region company representatives visited a potential site in Rostov where the plant might be built. The company also held talks with the governor of Yaroslavl region.

Octapharma AG Reports Earnings Results for the Year Ended December 31, 2013

Octapharma AG reported earnings results for the year ended December 31, 2013. For the year, the company reported net profit of EUR 124.40 million, compared to EUR 135.75 million for the year ended December 31, 2012. Net sales were EUR 1.15 billion, compared to EUR 915.65 million for the year ended December 31, 2012. Operating income was EUR 149.92 million, compared to EUR 136.78 million for the year ended December 31, 2012.

Similar Private Companies By Industry

Company Name Region
Metabomed Ltd. Europe
Delenex Therapeutics AG Europe
Oncoethix SA Europe
BioXpress Therapeutics SA Europe
Gnothis Holding SA Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Octapharma AG, please visit www.octapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.